Navigation Links
Global Bone Cement and Accessories Market Is Set to Expand from $630 Million in 2013 to Over $1 Billion by 2022
Date:9/3/2014

BURLINGTON, Mass., Sept. 3, 2014 /PRNewswire/ -- Decision Resources Group finds that the global market for bone cement and accessories will expand from $630 million in 2013 to over $1 billion by 2022. While the United States will continue to be the largest contributor of global revenues, the most growth will come from the rapidly expanding Brazilian, Indian and Chinese markets, where joint reconstruction volumes are increasing quickly and thus boosting demand for bone cement and accessories.

Other key findings from Decision Resources Group's coverage of the global bone cement and accessories market:

  • Impact of cementless implants: Although the bone cement market will be hampered by the use of cementless implants, the once rapid shift to cementless devices has slowed. Recent budget and reimbursement cuts have caused physicians to question whether the benefits of cementless implants justify their higher cost over cemented implants.
  • Premium-priced products: Despite pricing pressures, some higher-priced bone cement and accessory products will be increasingly adopted. For example, more expensive antibiotic bone cement is gaining popularity due to its ability to reduce the potential for infection. Higher-priced compatible and enclosed vacuum systems are also being adopted because they minimize the amount of monomer fumes in the operating room and reduce cement porosity.
  • Antibiotic bone cement in Japan: In 2014, the first antibiotic bone cement products—from Stryker and Biomet—entered the Japanese market, which will have a favorable impact on revenue growth. However, use of the products will be limited because they are only approved for very specific indications in Japan and there is a lack of awareness of antibiotic bone cement in the country.

Comments from Decision Resources Group Lead Analyst Deanna Edmunds:

  • "Stryker continues to lead the global market for bone cement and accessories, and the top players are all larger multinational companies that also sell related products, specifically reconstructive joint implants."
  • "The competitive landscape could see some change going forward. Zimmer's pending acquisition of Biomet could boost the combined company's position in the reconstructive implant space, which would have a positive impact on its position in the market for bone cement and accessories."

Additional Resources:

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cambrex To Present At Rodman & Renshaw 16th Annual Global Investment Conference
2. CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
3. Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
4. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
5. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
6. Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
7. Global Markets and Technologies for Molecular Imaging Devices
8. Bariatric Surgery: Global Markets for Services and Devices
9. Acute Heart Failure Global Clinical Trials Review, H2, 2014
10. Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden
11. Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):